Apple Health Outcome
17 compoundsin Regimen’s catalog are configured to track body fat via Apple Health. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
Body-fat percentage moves through two distinct levers: caloric deficit (driven by GLP-1 appetite suppression) and growth hormone signaling (driven by GH secretagogues such as CJC-1295, ipamorelin, tesamorelin, and MK-677). The two levers can be combined, but they target different compartments. GLP-1s reduce overall mass; GH secretagogues preferentially mobilize visceral and subcutaneous fat while better sparing lean tissue.
Tesamorelin is the only GH-releasing peptide with FDA approval for a body-composition indication — it reduces visceral adipose tissue (VAT) by roughly 15–20% over 26 weeks in HIV-associated lipodystrophy. CJC-1295 and ipamorelin do not have an equivalent regulatory dataset but operate on the same hypothalamic-pituitary pathway. AOD-9604, a fragment of GH (residues 176–191), has been studied in obesity with mixed results and is not approved.
For most users targeting body-fat percentage, the practical protocol combines a GLP-1 (for the deficit) with resistance training and protein floor (for lean retention) — with or without a GH secretagogue depending on goals and budget.
Anchor citation: Jastreboff AM et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
17 compounds
GHRH / GHRP Combination
A synergistic growth hormone releasing combination for body composition, sleep, and recovery.
Tracks
Tracks
Tracks
GHRH (1-29) Analog
Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.
Tracks
GHRH Analog (Egrifta)
Synthetic GHRH analog (modified GHRH 1-44) FDA-approved as Egrifta for HIV-associated lipodystrophy. Selectively reduces visceral adipose tissue and modestly elevates IGF-1 with a favorable safety profile relative to exogenous HGH.
Tracks
Tracks
Recombinant Human Growth Hormone
Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).
Tracks
Human Chorionic Gonadotropin
Glycoprotein hormone produced during pregnancy. Mimics luteinizing hormone (LH), stimulating Leydig cells in the testes to produce testosterone and maintain testicular volume. Commonly co-administered with TRT to preserve fertility and prevent testicular atrophy, or used as a post-cycle/restart bridge.
Tracks
Lonapegsomatropin (TransCon hGH)
Skytrofa is a once-weekly, long-acting growth hormone for children with growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug that slowly releases somatropin (hGH) over 7 days, providing stable GH levels with a single weekly injection instead of daily shots.
Tracks
Testosterone Ester (TRT)
Testosterone replacement therapy using a long-acting ester for stable hormone levels.
Tracks
Tracks
Tracks
Tracks
Tracks
Tracks
Tracks
ERRα/β/γ Agonist Exercise Mimetic
A pan-agonist of the estrogen-related receptor (ERR) family — most potent at ERRα — described as an 'exercise mimetic.' Preclinical mouse studies show increased energy expenditure, fatty acid oxidation, and reduced fat mass accumulation.
Tracks
Weight on the scale is total mass; body fat percentage is the ratio of adipose tissue to lean mass. A pure GLP-1 protocol without resistance training typically loses about 1 unit of lean mass for every 2–3 units of fat. A GLP-1 + lifting + adequate protein protocol can push that closer to 1:5 or better. Apple Health stores body-fat percentage if you log it from a bioimpedance scale or DEXA, and Regimen pulls it into the same Outcomes view as your dose history.
Tesamorelin has FDA-approved data for visceral fat reduction. The mechanism — pulsatile GH release — favors mobilization of intra-abdominal adipose tissue. CJC-1295 and ipamorelin act on the same pathway and are often used off-label for similar reasons, though they don’t have the same regulatory dataset. GLP-1s do not preferentially target belly fat, but because they shrink overall mass, abdominal circumference typically decreases too.
Many providers prescribe both classes concurrently for body-recomposition goals. They act on independent pathways (gut/hypothalamic appetite versus pituitary GH release), so there is no direct pharmacological conflict. Side effect profiles differ: GLP-1s tend toward GI symptoms; GH secretagogues toward water retention, fasting glucose elevation, and tingling in the extremities. Both warrant prescriber oversight.
Related reading
Best peptide tracker app in 2026
An honest multi-protocol comparison of Regimen, PeptIQ, Shotsy, MeAgain, and the GLP-1 calculator apps.
Other outcomes